Clinical Trial Update: Digoxin In NASH (CODIN) [Phase 2]

View source ↗

Summary

Phase 2 trial (CODIN) evaluating digoxin for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• DIGOXIN (Digoxin)

Snippet

Sponsor: Yale University | Conditions: NASH, NAFLD | Phase 2 | Status: RECRUITING